Warning: count(): Parameter must be an array or an object that implements Countable in /home/hmc/public_html/wp-content/plugins/formcraft3/formcraft-main.php on line 1013
Welcome to “PIONEER AF-PCI Trial Journal Club” Post Activity Assessment
Thank you and congratulations for attending this educational activity. Remember, continuous professional development is key to success and professional excellence.
This test is composed of 5 questions based on the information provided to you during the activity. You will have two attempts to complete this test. The 30 minutes which will allow enough time to search for the correct answers.
You must exceed the passing score (60%) in order to receive your certificate.
0 of 5 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 5 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
THANK YOU .
Question 1 of 5
2014 European Guidelines for management of antithrombotic therapy in patients with atrial fibrillation presenting with ACS and/or undergoing PCI recommends low intensity INR or low dose new oral anticoagulation agents (e.g. dabigatran 110 mg bid, rivaroxaban 15 mg od, or apixaban 2.5 mg bid) for triple therapy:CorrectIncorrect
Question 2 of 5
The major limitations for the PIONEER AF-PCI trial are:CorrectIncorrect
Question 3 of 5
2016 focused update of the Canadian Guidelines for management of atrial fibrillation prefers new oral anticoagulation agents over warfarin in triple therapy regimen based on high-quality evidence:CorrectIncorrect
Question 4 of 5
Bleeding rate with triple antithrombotic therapy may increase from 2.2% within the first month up to 12% within the first year:CorrectIncorrect
Question 5 of 5
What are the approved rivaroxaban dose (s) in USA or Europe:CorrectIncorrect